What Grace Therapeutics, Inc. does.

We are focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using our novel drug delivery technologies. We seek to apply new proprietary formulations to approved and marketed pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient drug delivery and increased patient compliance; all of which could result in improved patient outcomes. The active pharmaceutical ingredients used in the drug candidates under development by us may be already approved in a target indication or could be repurposed for use in new indications.

Our therapeutic pipeline consists of three unique clinical-stage drug candidates supported by an intellectual property portfolio of more than 79 granted and pending patents in various jurisdictions worldwide. These drug candidates aim to improve clinical outcomes in the treatment of rare and orphan diseases by applying proprietary formulation and drug delivery technologies to existing pharmaceutical compounds to achieve improvements over the current standard of care, or to provide treatment for diseases with no currently approved therapies.

Revenue and profit, by fiscal year.

More on GRCE.

• Grace Therapeutics, Inc. summary
• Grace Therapeutics, Inc. financial statements
• Grace Therapeutics, Inc. key metrics
• Grace Therapeutics, Inc. health scores and style box
• Grace Therapeutics, Inc. earnings
• Grace Therapeutics, Inc. dividends
• Grace Therapeutics, Inc. valuation
• Grace Therapeutics, Inc. ownership and insiders
• Grace Therapeutics, Inc. peers

Figures from Grace Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.